Gerald Commissiong (@G_Commish) header
Gerald Commissiong (@G_Commish) profile picture

Gerald Commissiong

@G_Commish

CBO @OSTherapies $OSTX, Interim Co-CEO @DataMedsAI $MEDS, Founder @Amarantusbio, Founder @TolloHealth @stanfordfball @myForzet @Galectovid @Tollovid #HABS

 New York, NY
tollohealth.com
Joined December 2012
  • Tweets50.3K
  • Following293
  • Followers5.3K
589Media
Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)Photo by Gerald Commissiong (@G_Commish)
Gerald Commissiong retweeted
Conor Browne (@brownecfm) profile picture
Conor Browne
@brownecfm16h
1. The bottom line: SARS-CoV-2 only emerged in late 2019. No-one can know the long-term effects of repeated infections, but with anosmia and cognitive dysfunction as common symptoms, the assumption I make is that there is a tsunami of early-onset neurocognitive diseases coming.
19
412
21
1,499
77,075
Gerald Commissiong retweeted
Dan Grunfeld (@Dan_Grunfeld) profile picture
Dan Grunfeld@Dan_GrunfeldOct 30
26-0. No. 1 in the country. All with just one NBA player. My 2004 Stanford basketball team is an epic case study in overachievement. My new book, WINNING WITHOUT PERMISSION, tells the inside story. It’s available for pre-order today! 👇🙏 a.co/d/0ijvmUGJ
Image from Dan Grunfeld (@Dan_Grunfeld)
11
18
8
217
47,264
Gerald Commissiong retweeted
Tom Kindlon (@TomKindlon) profile picture
Tom Kindlon@TomKindlonOct 29
News Release Early Paxlovid treatment was associated with modestly lower risks of Long COVID, post-acute hospitalization, and death among high-risk, nonhospitalized patients with COVID-19 [while no clear reduction...was observed among low-risk patients] eurekalert.org/news-releases…
News Release 28-Oct-2026 Early Paxlovid treatment was associated with modestly lower risks of Long COVID, post-acute hospitalization, and death among high-risk, nonhospitalized patients with COVID-19 Peer-Reviewed Publication PLOS image: Absolute risk, risk ratio, and risk difference of long COVID in the Paxlovid group versus the Non-treated group among high-risk patients. Early Paxlovid treatment was associated with modestly lower risks of Long COVID, post-acute hospitalization, and death among high-risk, nonhospitalized patients with COVID-19, while no clear reduction in Long COVID risk was observed among low-risk patients.

ALT News Release 28-Oct-2026 Early Paxlovid treatment was associated with modestly lower risks of Long COVID, post-acute hospitalization, and death among high-risk, nonhospitalized patients with COVID-19 Peer-Reviewed Publication PLOS image: Absolute risk, risk ratio, and risk difference of long COVID in the Paxlovid group versus the Non-treated group among high-risk patients. Early Paxlovid treatment was associated with modestly lower risks of Long COVID, post-acute hospitalization, and death among high-risk, nonhospitalized patients with COVID-19, while no clear reduction in Long COVID risk was observed among low-risk patients.

1
5
6
400
A study of nearly 500,000 adults found Paxlovid taken within 5 days of COVID-19 infection was linked to a 12% lower risk of Long COVID in high-risk adults. That's around 3 fewer Long COVID cases per 100 people treated. For lower-risk adults, researchers found no clear benefit.
Screenshot of a Bioengineer.org article published on 28 October 2026. - Headline: “Paxlovid cuts Long COVID risk in high-risk adults, large study finds.” - Category: Health. - Reading time: 2 minutes. - Main image: An older adult wearing a grey jumper sits at a kitchen table, holding a tablet in one hand. - Foreground: A glass of water and an open weekly pill organiser containing several colourful medications. - Background: A softly lit kitchen with cupboards and a window. - Main message: The article reports that a large study found Paxlovid was associated with a reduced risk of Long COVID among adults at high risk of severe COVID-19.

ALT Screenshot of a Bioengineer.org article published on 28 October 2026. - Headline: “Paxlovid cuts Long COVID risk in high-risk adults, large study finds.” - Category: Health. - Reading time: 2 minutes. - Main image: An older adult wearing a grey jumper sits at a kitchen table, holding a tablet in one hand. - Foreground: A glass of water and an open weekly pill organiser containing several colourful medications. - Background: A softly lit kitchen with cupboards and a window. - Main message: The article reports that a large study found Paxlovid was associated with a reduced risk of Long COVID among adults at high risk of severe COVID-19.

5
44
1
127
3,036
A new study estimates 75% of former NFL players who died between 2008–2023 had CTE. What comes next? @DannyWuerffel, former NFL QB and Heisman Trophy winner, believes difficult news can motivate us to come together, advance research, and make a difference. The findings are sobering. The work continues.
3
12
21
3,490
Gerald Commissiong retweeted
CBS News (@CBSNews) profile picture
CBS News
@CBSNewsOct 28
A new study from Boston University estimating that nearly 75% of NFL players who died over a 15-year period had signs of CTE in their brains is raising concern, and experts say it demonstrates the need to collect more data on the condition. cbsn.ws/4ByenkW
Experts weigh in on study estimating 75% of NFL players who died in recent years had signs of CTE

Experts weigh in on study estimating 75% of NFL players who died in recent years had signs of CTE

A new study from Boston University looks at the rate of the brain disease CTE in former NFL players who died between 2008 and 2023.

cbsnews.com
12
17
1
31
17,841
Gerald Commissiong retweeted
ABC News (@ABC) profile picture
ABC News
@ABCOct 28
Nearly 3 in 4 former NFL players had chronic traumatic encephalopathy (CTE) at the time of their death, according to a new study published in the Journal of the American Medical Association. Read more: abcnews.visitlink.me/D-NreG
Image from ABC News (@ABC)
9
37
7
113
33,914
Toss in the neurological damage from COVID and they are screwed. scientificamerican.com/artic…
Landmark study finds three in four NFL players die with CTE

Landmark study finds three in four NFL players die with CTE

The staggering new estimate is based on an analysis of thousands of former players’ medical records

scientificamerican.com
2
33
3
115
3,450
Gerald Commissiong retweeted
Daily Mail US (@Daily_MailUS) profile picture
Daily Mail US
@Daily_MailUSOct 29
Bombshell new study finds three quarters of ex-NFL stars who died between 2008 and 2023 had CTE trib.al/PHhiuDk
Image from Daily Mail US (@Daily_MailUS)
5
11
2,564
Gerald Commissiong retweeted
CNN (@CNN) profile picture
CNN
@CNNOct 28
A new study estimates about 3 in 4 former National Football League players who died between 2008 and 2023 had chronic traumatic encephalopathy — an even higher level than identified in another recent study of former players. cnn.it/48mGfey
Image from CNN (@CNN)
51
70
7
206
104,406
Gerald Commissiong retweeted
CBS News (@CBSNews) profile picture
CBS News
@CBSNewsOct 28
Nearly 75% of NFL players who died between 2008 and 2023 had CTE, a new study out of Boston University finds. cbsn.ws/48mT7kQ
Nearly 75% of former NFL players who died from 2008 to 2023 had CTE, Boston University study finds

Nearly 75% of former NFL players who died from 2008 to 2023 had CTE, Boston University study finds

Nearly 75% of NFL players who died between 2008 and 2023 had CTE, a new study out of Boston University finds.

cbsnews.com
15
70
26
205
56,725
Gerald Commissiong retweeted
Dave A Ricks (@DaveARicks) profile picture
Dave A Ricks
@DaveARicksOct 29
In other news, US projected to save billions expanding access to Obesity care according to independent group at USC 👇🏻@DrOz @DrOzCMS medrxiv.org/content/10.64898…
Projected Health and Economic Effects of Expanded Access to Anti-Obesity Medications in Medicare

Projected Health and Economic Effects of Expanded Access to Anti-Obesity Medications in Medicare

Background: The CMS GLP-1 Bridge demonstration (July 2026-December 2027) expands access to GLP-1s for additional eligible Medicare Part D beneficiaries for a $50 monthly copay. Its long-run value...

medrxiv.org
10
12
4
128
23,946
Gerald Commissiong retweeted
NBC News (@NBCNews) profile picture
NBC News
@NBCNewsOct 29
An estimated 75% of professional football players who died over a 15-year span had signs of chronic traumatic encephalopathy, or CTE, a study finds. nbcnews.com/health/health-ne…
Study estimates 75% of NFL players who died over 15-year span had CTE

Study estimates 75% of NFL players who died over 15-year span had CTE

The study looked at NFL players who died from 2008 to 2023. Not everyone with signs of the disease in the brain develops symptoms.

nbcnews.com
4
11
1
24
16,276
Gerald Commissiong retweeted
ABC News (@ABC) profile picture
ABC News
@ABCOct 28
Nearly 3 in 4 former NFL players had chronic traumatic encephalopathy (CTE) at the time of their death, according to a new study published in the Journal of the American Medical Association. abcnews.link/gh3lZaJ
New study estimates about 3 in 4 former NFL players had CTE

New study estimates about 3 in 4 former NFL players had CTE

Nearly 3 in 4 former NFL players had chronic traumatic encephalopathy (CTE) at the time of their death, according to a new study published Wednesday.

abcnews.com
13
40
10
108
41,841
Gerald Commissiong retweeted
U.S. FDA (@FDA) profile picture
U.S. FDA
@FDAOct 28
Today, FDA kicked off its Rare Disease Framework Initiative with a public meeting, co-hosted by @ReaganUdall. Thanks to all who joined for your input, candor & vision. With only 5% of rare diseases having an approved treatment, the status quo isn't enough — we must do more. FDA Acting Commissioner @FDA_KyleD shared with the attendees that the “urgency of the need has not changed, but now we — the agency, drug developers, researchers, and patients — are ready to meet that need together.”
Image from U.S. FDA (@FDA)
Image from U.S. FDA (@FDA)
29
36
11
193
22,658
$MEDS
Image from Gerald Commissiong (@G_Commish)
Image from Gerald Commissiong (@G_Commish)
Gerald Commissiong (@G_Commish) profile pictureGerald Commissiong
@G_CommishOct 21
$MEDS
Image from Gerald Commissiong (@G_Commish)
Image from Gerald Commissiong (@G_Commish)
1
1
5
678
Gerald Commissiong retweeted
DataMEDSAI (@DataMEDSAI) profile picture
DataMEDSAI@DataMEDSAIOct 28
In healthcare, the real issue isn't the prescription. It's everything around it. Interim Co-CEO Gerald Commissiong joined @FINTECHTVglobal to discuss how DataMEDS AI connects patient records and labs on the blockchain. $MEDS terminal.fintech.tv/fintecht…
Image from DataMEDSAI (@DataMEDSAI)
3
4
440
Gerald Commissiong retweeted
Dr. Oz CMS (@DrOzCMS) profile picture
Dr. Oz CMS
@DrOzCMSOct 27
Cell and gene therapies can change what’s possible for patients living with rare and severe diseases. Cost shouldn’t put that possibility out of reach. CMS is expanding our Cell and Gene Therapy Access Model to help more Medicaid patients access these life-changing treatments. Learn more about the CGT 2.0 Model: go.cms.gov/CGT
CMS Innovation Center (@CMSinnovates) profile pictureCMS Innovation Center@CMSinnovatesOct 27
At Cleveland Clinic today, CMS Innovation Center Director Abe Sutton, @DrOzCMS, and @FDA_KyleD announced that CMS will invite manufacturers of other cell and gene therapies to apply to the CGT Access Model. Learn more: go.cms.gov/CGT
33
93
11
472
23,177
Gerald Commissiong retweeted
FINTECH.TV (@FINTECHTVglobal) profile picture
FINTECH.TV
@FINTECHTVglobalOct 28
Staying on a weight loss drug is about more than the drug itself. @G_Commish, Interim Co-CEO of @DataMEDSAI, tells @Johnyonthefloor “it is not just the drug, it is the behaviour around the drug.”
4
7
562
Gerald Commissiong retweeted
Laura Miers (@LauraMiers) profile picture
Laura Miers
@LauraMiersOct 27
Adding this to the “SARS-CoV-2 persists in almost every organ & organ system indefinitely” mega thread.
Reality Check Marker (@RealCheckMarker) profile pictureReality Check Marker@RealCheckMarkerJul 21
SARS.RF.5 gut persistence: SARS variants are getting better at persistent infection. Only now do we know BA.2.86 and JN.1 infected small-intestine models more efficiently than Omikron. #LongCOVID is #AirborneAIDS so #WearN95
5
12
395
Load more